LP106

LP106 is a preclinical-stage long-acting injectable (LAI) formulation being developed by Xiamen LiZhuo Pharmaceutical for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The drug is designed using a controlled or sustained-release delivery system, which is intended to provide a prolonged therapeutic effect from a single injection, thereby reducing the burden of daily oral dosing and potentially improving patient compliance. While the specific active pharmaceutical ingredient has not been formally disclosed in the sponsor's public pipeline, the formulation targets the management of ADHD symptoms through the central nervous system. Xiamen LiZhuo Pharmaceutical specializes in complex injection technologies, including microspheres and in-situ forming gels, which are likely employed in the development of LP106 to achieve its sustained-release profile.

Other names

LP106长效注射剂LP106 Long-Acting InjectableLP-106 Long-Acting InjectableLP 106 Long-Acting Injectable